AI assistant
Aclaris Therapeutics, Inc. — Director's Dealing 2022
Feb 1, 2022
33670_dirs_2022-02-01_fb5dff95-ae08-48b9-b1d1-d7af996c36b9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aclaris Therapeutics, Inc. (ACRS)
CIK: 0001557746
Period of Report: 2022-02-01
Reporting Person: Loerop James (Chief Business Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-02-01 | Employee Stock Option (Right to Buy) | $11.58 | A | 155000 | Acquired | 2032-01-31 | Common Stock (155000) | Direct |
| 2022-02-01 | Restricted Stock Units | $ | A | 45000 | Acquired | Common Stock (45000) | Direct |
Footnotes
F1: Exercisable with respect to 25% of the shares subject to the option vesting in four equal annual installments beginning on February 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
F2: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F3: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting
Person's continuous service with the Issuer as of the applicable vesting date.